VBI Vaccines Inc. [NASDAQ: VBIV] stock went on an upward path that rose over 9.48% on Monday, amounting to a one-week price decrease of less than -3.86%. The company report on August 5, 2020 that VBI Vaccines Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development.
– Government of Canada will support advancement of VBI’s coronavirus program through Phase 2 clinical development.
– Pre-clinical data are expected to enable selection of clinical candidates in Q3 2020 and the initiation of clinical studies by the end of 2020.
Over the last 12 months, VBIV stock rose by 477.62%. The average equity rating for VBIV stock is currently 1.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $921.32 million, with 231.20 million shares outstanding and 150.88 million shares in the current float. Compared to the average trading volume of 13.78M shares, VBIV stock reached a trading volume of 6786606 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on VBI Vaccines Inc. [VBIV]:
Oppenheimer have made an estimate for VBI Vaccines Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on January 16, 2019. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on November 01, 2017, representing the official price target for VBI Vaccines Inc. stock. Previously, the target price had yet another raise to $6, while Laidlaw analysts kept a Buy rating on VBIV stock.
The Average True Range (ATR) for VBI Vaccines Inc. is set at 0.57, with the Price to Sales ratio for VBIV stock in the period of the last 12 months amounting to 506.22. The Price to Book ratio for the last quarter was 7.26.
VBIV Stock Performance Analysis:
VBI Vaccines Inc. [VBIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.86. With this latest performance, VBIV shares dropped by -35.41% in over the last four-week period, additionally plugging by 160.46% over the last 6 months – not to mention a rise of 477.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for VBIV stock in for the last two-week period is set at 48.83, with the RSI for the last a single of trading hit 47.70, and the three-weeks RSI is set at 50.95 for VBI Vaccines Inc. [VBIV]. The present Moving Average for the last 50 days of trading for this stock 3.71, while it was recorded at 3.71 for the last single week of trading, and 1.86 for the last 200 days.
Insight into VBI Vaccines Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and VBI Vaccines Inc. [VBIV] shares currently have an operating margin of -2075.96 and a Gross Margin at -310.09. VBI Vaccines Inc.’s Net Margin is presently recorded at -2467.94.
Return on Total Capital for VBIV is now -42.55, given the latest momentum, and Return on Invested Capital for the company is -54.78. Return on Equity for this stock declined to -58.82, with Return on Assets sitting at -42.20. When it comes to the capital structure of this company, VBI Vaccines Inc. [VBIV] has a Total Debt to Total Equity ratio set at 18.47. Additionally, VBIV Total Debt to Total Capital is recorded at 15.59, with Total Debt to Total Assets ending up at 13.34. Long-Term Debt to Equity for the company is recorded at 0.93, with the Long-Term Debt to Total Capital now at 0.78.
Reflecting on the efficiency of the workforce at the company, VBI Vaccines Inc. [VBIV] managed to generate an average of -$438,504 per employee. Receivables Turnover for the company is 17.28 with a Total Asset Turnover recorded at a value of 0.02.
VBIV Stock EPS
With the latest financial reports released by the company, VBI Vaccines Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -9.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for VBIV.
VBI Vaccines Inc. [VBIV] Insider Position Details
There are presently around $392 million, or 44.45% of VBIV stock, in the hands of institutional investors. The top three institutional holders of VBIV stocks are: PERCEPTIVE ADVISORS LLC with ownership of 55,042,465, which is approximately 19.784% of the company’s market cap and around 5.26% of the total institutional ownership; BLACKROCK INC., holding 13,076,588 shares of the stock with an approximate value of $52.11 million in VBIV stocks shares; and VANGUARD GROUP INC, currently with $24.15 million in VBIV stock with ownership of nearly 89.965% of the company’s market capitalization.
Positions in VBI Vaccines Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 77 institutional holders increased their position in VBI Vaccines Inc. [NASDAQ:VBIV] by around 23,338,092 shares. Additionally, 25 investors decreased positions by around 3,054,317 shares, while 9 investors held positions by with 72,083,140 shares. The mentioned changes placed institutional holdings at 98,475,549 shares, according to the latest SEC report filing. VBIV stock had 39 new institutional investments in for a total of 6,040,106 shares, while 9 institutional investors sold positions of 522,652 shares during the same period.